Durect corporation announces sale of alzet® product line to lafayette instrument co. for $17.5 million

Cupertino, calif. , nov. 25, 2024 /prnewswire/ -- durect corporation (nasdaq: drrx), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its alzet® line of osmotic pumps to lafayette instrument co. (lic), a portfolio company of branford castle partners ii, l.p.
DRRX Ratings Summary
DRRX Quant Ranking